Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024
ALPCO Announces the Commercial Launch of Its FDA 510(K) Cleared Calprotectin Immunoturbidimetric Assay
American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions. In July... - December 19, 2023
GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio
GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio. This comes as a testament to the company’s dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027. Currently,... - October 03, 2023
ALPCO Receives FDA 510(k) Clearance for the Calprotectin Immunoturbidimetric Assay
American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, today announced recent FDA 510(k) clearance of its Calprotectin Immunoturbidimetric Assay. The Calprotectin Immunoturbidimetric (IT) Assay is now IVDD and 510(k)-cleared for in... - June 15, 2023
Thermo Fisher Partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
ALPCO-GeneProof, a global leader in diagnostics, and Thermo Fisher announced a strategic partnership that brings the TaqPath Menu | GeneProof PCR kits to market. The partnership combines the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust... - April 17, 2023
American Laboratory Products Company Merges with GeneProof
American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader... - April 21, 2022
ALPCO Announced Its Support of the Ukrainian People in a Company-Wide Communication to Its Employees
ALPCO (Salem, NH) announced its support of the Ukrainian people in a company-wide communication to its employees. The message outlined the company's contribution to aid refugees through the American Red Cross and Project Hope in the amount of $5,000 each. Additionally, ALPCO is offering an... - March 16, 2022
MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market
ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022
Erica Cai Named ALPCO’s Summer 2020 Diabetes Research Travel Grant Recipient
Today ALPCO announced Erica Cai from Harvard Medical School as the latest recipient of its Diabetes Research Travel Grant. Dr. Cai is a postdoctoral fellow from the Joslin Diabetes Center researching the mechanism of autoimmunity that leads to beta cell destruction and type 1 diabetes (T1D). Dr. - November 10, 2020
Ampersand Capital Partners Acquires American Laboratory Products Company
American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s worldwide growth initiatives, including the... - September 21, 2020
Marlena Holter Named ALPCO’s Winter 2020 Diabetes Research Travel Grant Recipient
ALPCO's Winter 2020 Diabetes Research Travel Grant has been awarded to Marlena Holter, a DVM/PhD candidate from Cornell University’s College of Veterinary Medicine. Ms. Holter’s novel research focuses on GLP-1 regulated glucose regulation following vertical sleeve gastrectomy surgery to define the mechanisms underlying type 2 diabetes remission and metabolic improvement following bariatric surgery. - April 14, 2020
ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award
ALPCO announced the submission deadline for its Winter 2020 Diabetes Research Travel Grant Award. Each recipient is awarded up to $2500 to present their research at a relevant conference and a $2500 product credit. - December 04, 2019
ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA
ALPCO's new STELLUX® Chemiluminescence Glucagon ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples. - November 06, 2019
ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenges of differentiating IBD from IBS. - October 30, 2019
ALPCO Announces January 2019 Young Investigator Award Recipient of Its Diabetes Research Travel Grant
ALPCO awards its January 2019 Diabetes Research Travel Grant to Lisa Volpatti at Massachusetts Institute of Technology. - February 05, 2019
ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA
ALPCO announces launch of its new highly specific FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. - October 23, 2018
ALPCO Announces Inaugural Young Investigators Award Recipient
ALPCO announces the first recipient of its new young investigators award, the Diabetes Research Travel Grant. - October 17, 2018
ALPCO’s Quality Management System Receives ISO 13485:2016 Certification
ALPCO announces that its quality management system recently received the distinguished ISO 13485:2016 certification from Intertek to ensure the quality, safety and efficacy of its products in the clinical diagnostics field. - October 09, 2018
ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo. - July 25, 2018
ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models
ALPCO and InSphero announce partnership to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. - July 24, 2018
ALPCO Releases STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA to Accurately Quantify Fasted Levels
ALPCO, a leading producer of research and clinical immunoassays, recently announced the launch of its STELLUX® Chemi Active GLP-1 (7-36) amide ELISA. The chemiluminescence ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25... - July 17, 2018
ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions
ALPCO will promote its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at the American Diabetes Association’s 78th Scientific Sessions June 22-26, 2018 in Orlando, FL. - June 19, 2018
ALPCO to Highlight Assay Qualification Program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo
ALPCO announced it will feature a variety of products supported by its assay qualification program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3, 2017. Among these products is the Easy Stool Extraction Device and a Therapeutic Drug Monitoring ELISA portfolio. - July 25, 2017
ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA's 77th Scientific Sessions
The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader. - June 07, 2017
ALPCO and InSphero Collaborate at the ADA's 77th Scientific Sessions to Advance Metabolic Disease Research
ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays. - June 06, 2017
ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®
ALPCO will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this launch are two Zonulin ELISAs for the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for IBD. - May 02, 2017
New Gastrointestinal Pathogen Assays Available from ALPCO
ALPCO is now offering a line of research assays for the investigation of common bacterial and parasitic gastrointestinal (GI) pathogens including Giardia lamblia, Cryptosporidium spp., Blastocystis hominis, Entamoeba histolytica/dispar, and Clostridium difficile. These assays can be used to... - November 15, 2016
New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1
ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA, the most sensitive active GLP-1 assay on the market. - November 09, 2016
ALPCO Releases Versatile and Economical Chemiluminescent Plate Reader
ALPCO has launched its new STELLUX® Chemiluminescent Plate Reader, an economical and versatile system for any size lab. - September 20, 2016
ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes
ALPCO has released new and improved versions of their Total Adiponectin and HMW & Total Adiponectin ELISAs which allow researchers to confidently measure adiponectin for the study of high molecular weight (HMW) to total ratios. - August 17, 2016
ALPCO Releases New Broad Range Periostin ELISA
ALPCO now has a new broad range Periostin ELISA capable of measuring elevated levels of periostin consistent with current research. - June 07, 2016
ALPCO’s Bioactive Leptin ELISA Allows Researchers to Differentiate Between Leptin Resistance and Non-functional Leptin
ALPCO recently announced the release of its Bioactive Leptin ELISA, offering diabetes and obesity researchers a new tool to differentiate between leptin resistance and non-functional leptin. The assay allows for the measurement of leptin in human serum through the process of binding leptin to... - April 26, 2016
ALPCO's New Chemiluminescent IL-6 ELISA Delivers Flexibility and Cost Savings
ALPCO announced the launch of its new STELLUX® Chemi Human IL-6 ELISA - the first cytokine assay in the STELLUX® Chemiluminescence product line. - April 06, 2016
ALPCO's New NT-proBNP ELISA Offers Cost Savings and Flexibility
ALPCO recently announced the release of its new NT-proBNP (1-76) ELISA, offering researchers investigating cardiovascular disease, kidney disease, and diabetes with a flexible, user friendly and cost effective tool. The assay is highly characterized to measure changes in levels of NT-proBNP, and... - February 23, 2016
ALPCO Releases New Basophil Activation Test Validated for the Evaluation of Kinase Inhibitors in Early Drug Development
ALPCO has released its new InhibiScreen Basophil Activation Test (BAT) which was developed and validated specifically for the evaluation of kinase inhibitors during early drug development. - February 16, 2016
ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step, allowing labs to improve sample processing time by up to 86%. - January 26, 2016
ALPCO Releases New STELLUX® Chemiluminescent Adiponectin ELISAs
ALPCO has launched its new STELLUX® Chemiluminescent Total Adiponectin and HMW Adiponectin ELISAs. - August 25, 2015
ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement
Starting on July 1, Cisbio US, Inc. will have exclusive access to ALPCO's colorimetric and STELLUX® Chemiluminescent Diabetes and Obesity products. - July 01, 2015
ALPCO Launches New and Improved Website for Customers
ALPCO recently launched a brand new website. The site was designed and developed to offer their customers a new and improved experience when searching for and buying immunoassay products. The website’s key features allow for more intuitive browsing and navigation on any device. ALPCO’s... - June 16, 2015
ALPCO Releases New Chemiluminescent Human C-peptide ELISA
ALPCO adds to their STELLUX® Chemiluminescent line of assays with the launch of the new Human C-peptide ELISA. - December 10, 2014
New Pancreatic Cell Antibodies from ALPCO Allow Researchers to Identify and Isolate Major Pancreatic Cell Types
A new menu of pancreatic cell antibodies for the identification and isolation of major human pancreatic cell types is now available from ALPCO. - August 07, 2014
ALPCO Launches Antibodies Supporting Pancreatic Cancer Research
In response to recent reports that pancreatic cancer deaths are on the rise globally, ALPCO has released a line of pancreatic antibodies to provide the research community with reliable tools that can be used to better analyze and understand pancreatic cancer. - July 29, 2014
ALPCO Expands EuroFlow™ Product Offering with the Addition of Plasma Cell Dyscrasias Screening Tube
ALPCO has expanded EuroFlow™ product offering with addition of the Plasma Cell Screening Tube from Cytognos S.L. - April 03, 2014
ALPCO Releases STELLUX™ Chemiluminescent Human Intact Proinsulin ELISA
ALPCO has launched their new STELLUX™ Chemi Human Intact Proinsulin ELISA, the latest addition to their chemiluminescent product line. - February 18, 2014
ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House
ALPCO expands test portfolio for clinical and hospital laboratory customers with the release of a FDA 510(k) cleared 25-OH Vitamin D Total ELISA. - January 22, 2014
ALPCO Releases STELLUX™ Chemiluminescence Human Total Proinsulin ELISA
A new Human Total Proinsulin ELISA is launched in ALPCO's STELLUX™ Chemiluminescent line of assays. - November 19, 2013
ALPCO Expands Product Offering with Addition of Mouse-Specific Flow Cytometry Reagents
Earlier this year, ALPCO began offering flow cytometry reagents and data analysis software. As promised, the company has recently added high quality and affordable mouse reagents to their growing flow cytometry portfolio. Among the 600 new mouse reagents are antibodies for CD3, CD4, CD8 and... - October 29, 2013
ALPCO Launches STELLUX™ Chemiluminescent Human Insulin ELISA
ALPCO releases second chemiluminescent assay in STELLUX™ product line. - October 24, 2013
ALPCO to Distribute NAG Assays from PPR Diagnostics
New distribution agreement allows ALPCO to distribute NAG assays from PPR Diagnostics. - June 13, 2013
Mouse Osteopontin ELISA Now Available from ALPCO
ALPCO launches the second species-specific kit in a line of Osteopontin ELISAs. - May 31, 2013